Disclosure
This article contains affiliate links. Inner Balance and Winona, both reviewed in the second half, run affiliate programmes we participate in, and we may earn a commission if you sign up through our links. We do not accept payment for favourable coverage — you will see below that we report what professional bodies say about the product category both of them sell. Read our full affiliate disclosure.
This page is informational only and is not medical advice. Hormone therapy has real risks and benefits that depend on your personal and family history. Discuss it with a licensed clinician.
The short version
For PCOS, the GLP-1 evidence is genuinely good — insulin resistance is the underlying problem in most cases, and these drugs act on it directly. For menopause, the picture is about body composition: falling oestrogen shifts fat to the abdomen and accelerates muscle loss, which makes protein and resistance training matter more during treatment, not less.
On hormone therapy itself, the distinction that matters is not bioidentical versus synthetic. It is FDA-approved versus compounded — and ACOG advises against routine use of compounded bioidentical hormone therapy where approved options exist.
PCOS: Where the GLP-1 Evidence Is Strongest
Polycystic ovary syndrome is frequently framed as a reproductive condition, but metabolically it is largely an insulin resistance condition — documented in clamp studies in roughly 75% of women with PCOS. That is precisely the mechanism GLP-1 receptor agonists act on, which is why the evidence here is stronger than for most off-label uses.
- A meta-analysis of randomised controlled trials found GLP-1 agonists promoted both weight loss and hormonal regulation in women with PCOS and obesity.
- Visceral fat specifically responds. Liraglutide reduced visceral abdominal fat in women with PCOS — the deep fat most strongly linked to insulin resistance and inflammation, and the depot most relevant to long-term risk.
- The mechanism goes beyond weight. GLP-1 receptor agonists also increase glucose transporter expression in insulin-dependent tissues, reduce inflammation and oxidative stress, and modulate lipid metabolism.
- Cycles may become more regular. Some patients report more predictable menstrual cycles as insulin resistance improves, which is consistent with the underlying physiology.
- Clinicians have noticed. Among women with PCOS, semaglutide or tirzepatide prescribing rose from 2.4% in 2021 to 17.6% in 2025 — more than a sevenfold increase in four years.
An important caution for PCOS
Improving insulin resistance can restore ovulation. That is generally a good outcome — but it means fertility may return unexpectedly, and GLP-1 medications are not appropriate in pregnancy. Manufacturers advise discontinuing well before a planned pregnancy. If you have PCOS, are of reproductive age and are not seeking pregnancy, discuss contraception with your prescriber before starting.
Menopause: A Body Composition Problem
The midlife weight change most women describe is real and physiological. As oestrogen falls, fat storage shifts from subcutaneous towards visceral abdominal fat — the more metabolically harmful pattern. At the same time, muscle mass declines with age and with oestrogen loss, and because muscle is metabolically active, losing it lowers resting energy expenditure. The result is that the same diet that maintained weight at 40 may not at 50.
This has a direct implication for GLP-1 treatment. Rapid weight loss of any kind takes some lean mass with the fat, and that matters more when you are starting from a lower muscle baseline and already facing age-related sarcopenia risk. Two countermeasures are well established: eat enough protein, and do resistance training throughout treatment. Our guide to protein and satiety covers the first, and it does double duty — protein supports both muscle retention and appetite control.
Where Hormone Therapy Fits — and the Compounded Question
Hormone therapy is a legitimate, evidence-based treatment for menopausal symptoms. It is not a weight-loss treatment, and should not be sold as one. Where it becomes relevant to this site is that a growing number of telehealth companies now offer hormone therapy and weight-loss medication side by side, and readers deserve to understand what they are being offered.
The critical distinction is not the one the marketing emphasises. “Bioidentical” simply means the hormone molecule is structurally identical to the one your body makes — and several FDA-approved products are bioidentical too, including approved estradiol and micronised progesterone. The distinction that carries clinical weight is FDA-approved versus compounded.
What professional bodies actually say
ACOG's clinical consensus is that compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved formulations exist, and that clinicians should counsel patients that FDA-approved therapies are recommended over compounded ones.
ACOG has also observed that many compounding pharmacies use “bioidentical hormone” as a marketing term implying these preparations are more natural or safer than FDA-approved medications, and that evidence to support those claims is lacking. The 2020 National Academies review of compounded bioidentical hormone therapy reached similar conclusions about the thinness of the evidence.
The narrower legitimate case, acknowledged by the North American Menopause Society, is a patient who genuinely cannot use an approved product — for example because of an allergy to an ingredient in it.
If that argument sounds familiar, it should: it is structurally the same as the compounded GLP-1 question we cover across our provider reviews. A compounded preparation has not been through FDA review for potency, purity or consistency, whoever makes it.
Inner Balance, Reviewed
Inner Balance is a women's hormone telehealth platform founded by Dr Sarah Daccarett, MD, a board-certified physician specialising in women's hormonal health. Its flagship product, Oestra, is a prescription vaginal cream combining bioidentical estradiol and progesterone in a single daily application, aimed at perimenopause, menopause, PCOS and endometriosis.
| Detail | What is published |
|---|---|
| Price | $199/month for the first six months, then $99.50/month ongoing — covering the medical evaluation, the medication and free shipping. HSA/FSA eligible. |
| Formulation | 100mg progesterone and 3mg estradiol in a cream base — actual amounts published, which many compounded providers do not do. |
| Regulatory status | Compounded. Not FDA-approved. See the ACOG position above. |
| Guarantee | A six-month money-back guarantee on the flagship product. |
| Clinical lead | Founder named publicly: Dr Sarah Daccarett, MD, board-certified. |
What it does well
Several things, genuinely. It names its founding physician rather than hiding behind “licensed providers”. It publishes the actual hormone quantities in the formulation, which is more label transparency than most compounded operations offer. It backs the product with a six-month money-back guarantee. And its pricing runs the opposite way to the industry norm: rather than a cheap first month followed by a step up, the price halves after six months. After reviewing dozens of providers whose advertised rate is the least representative number they have, that is a refreshing structure.
The reservation
Oestra is a compounded preparation, and FDA-approved estradiol and progesterone products — including vaginal formulations — already exist. That places it squarely within the category ACOG advises against prescribing routinely. None of that makes it unsafe or the company disreputable; it means there is an approved alternative your doctor can prescribe, and the professional consensus is to try that first. Ask specifically why a compounded preparation is being recommended over an approved one in your case, and expect a substantive answer.
A named board-certified founder, published formulation amounts, a six-month guarantee and pricing that falls rather than rises — this is better run than most of what we review. The score reflects the category rather than the company: compounded bioidentical hormone therapy is something ACOG advises against prescribing routinely where approved options exist, and approved options do exist.
Hormone therapy · Not a weight-loss treatment · Ask about FDA-approved options too
Winona, Reviewed — and the Willow Connection
Winona is the other menopause telehealth service we are asked about most, and it is worth setting beside Inner Balance because it solves the same problem at a very different price. It prescribes bioidentical HRT through board-certified doctors across several delivery formats — oral, vaginal, transdermal patches — with free shipping and free unlimited follow-ups, and no membership fee.
One relationship is worth knowing about, because neither company leads with it: Winona does not prescribe GLP-1 medications, but its sister company Willow does, and the two are designed to be used alongside each other. If you are considering both hormone therapy and weight-loss medication, that is a genuinely convenient pairing — and our Willow review sets out what to check on the GLP-1 side, including that its order becomes final once a prescription is issued.
| Winona | Inner Balance | |
|---|---|---|
| Price | From $39/mo progesterone, $54/mo estrogen tablets, $89/mo for the popular estrogen cream plus progesterone. No membership fee. | $199/mo for six months, then $99.50/mo. Includes evaluation and shipping. |
| Formats | Oral, vaginal and transdermal patches — more choice. | A single vaginal cream combining both hormones. |
| Disclosure | Board-certified doctors, but no named clinical lead and no published hormone amounts on the homepage. | Names its founding physician and publishes exact amounts (100mg progesterone, 3mg estradiol). |
| Regulatory status | Compounded. Same ACOG caveat as above. | Compounded. Same ACOG caveat as above. |
| GLP-1 | Not offered — routed to sister company Willow. | Not offered. |
On price, Winona wins clearly — $89/month for a combined regimen against $199/month for Inner Balance's first six months. On disclosure, Inner Balance wins: it names its founding physician and publishes the actual hormone quantities, neither of which Winona does on its homepage. Both are compounded, so the ACOG position above applies equally to both, and the first question for either remains why a compounded preparation rather than an approved one.
Substantially cheaper than the alternative here, with more delivery formats, no membership fee and unlimited follow-ups included. It discloses less than Inner Balance does about who is behind it and what is in the preparation, and it sits in the same compounded category ACOG advises against prescribing routinely.
Hormone therapy · No GLP-1 · Ask about FDA-approved options too
Contraception, Fertility and the Interaction Only One Drug Has
This is the most important thing on this page and it is barely discussed anywhere: tirzepatide can make oral contraceptives less effective, and semaglutide does not. Those two drugs get talked about interchangeably, and here they genuinely are not.
The tirzepatide label recommendation
The FDA label for tirzepatide advises patients using oral hormonal contraceptives to switch to a non-oral method, or add a barrier method, for four weeks after starting the medication and four weeks after each dose increase.
Tirzepatide titrates every four weeks — 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg. Working all the way up means six separate windows in which your pill may not be doing its job. That is most of the first six months.
The mechanism is the same delayed gastric emptying that makes these drugs work, and it is most pronounced immediately after starting and immediately after each dose step. The numbers from the drug-interaction study are not subtle: after a single 5mg dose of tirzepatide, peak concentrations of contraceptive hormones fell by 59% for ethinyl estradiol, 66% for norgestimate and 55% for norelgestromin, with total exposure down by roughly 20%.
Semaglutide is the contrast that makes the point. Studies of semaglutide found no clinically significant effect on the bioavailability of oral contraceptives, and its label carries no equivalent recommendation. If you are on semaglutide, this particular problem is not yours. If you are on tirzepatide — Mounjaro or Zepbound — it is, and the fix is straightforward once you know: a non-oral method, or condoms through each window.
“Ozempic babies” are two things at once
The unplanned pregnancies people report on these medications have two separate causes, and conflating them obscures both. The first is the contraceptive interaction above, which is tirzepatide-specific. The second is that weight loss can restore ovulation — particularly in PCOS, as covered at the top of this article — in women who had come to assume they were unlikely to conceive. Someone who has not needed reliable contraception in years may suddenly need it, and nothing about the medication announces that.
If you are planning a pregnancy
GLP-1 medications are not for use in pregnancy. Because of their long half-lives, the guidance for both semaglutide and tirzepatide is to stop at least two months before a planned conception, not when you get a positive test.
If you conceive unexpectedly while taking one, contact your prescriber promptly rather than waiting for a scheduled appointment.
Hers, and Why the Question Belongs to Whoever Sells You Both
Hers is the women's arm of Hims & Hers, and it is the clearest example of why the section above matters commercially. It sells GLP-1 weight-loss treatment and birth control on the same account, to the same customer, which makes it exactly the kind of service that should be joining those dots for you — and a fair thing to test when you sign up. Ask, before you pay, what its clinicians do about contraception if you are prescribed tirzepatide.
On the commercial side it is the same platform and the same pricing as Hims. The Weight Loss Membership is $39 for the first month and $149/month afterwards, with medication billed separately — the oral Wegovy pill from $149. Since the March 2026 settlement with Novo Nordisk, Hims & Hers no longer advertises compounded GLP-1s and has moved to FDA-approved medication, with compounded semaglutide limited to cases of medical necessity, so do not count on it being available. Our full Hims & Hers review covers the settlement, the pricing arithmetic and how it compares against buying brand-name medication direct from the manufacturer — which, for cash payers, is substantially cheaper.
Worth being clear about
Hers is a telehealth platform, not a specialist in this interaction, and buying both products from one company does not by itself guarantee anyone has checked them against each other. Say it out loud in your intake: “I take an oral contraceptive.” Do not assume the form captured it.
$39 first month then $149/mo membership · Medication billed separately · Tell them about your contraception
Frequently Asked Questions
Does a GLP-1 make birth control less effective?
Tirzepatide can; semaglutide does not appear to. The FDA label for tirzepatide (Mounjaro, Zepbound) advises women using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting and for four weeks after each dose increase — and since tirzepatide titrates every four weeks through six dose levels, that covers most of the first six months. In a drug-interaction study, a single 5mg dose reduced peak contraceptive hormone concentrations by 55–66% and total exposure by roughly 20%. Studies of semaglutide found no clinically significant effect on oral contraceptive bioavailability, and its label carries no equivalent warning.
Can a GLP-1 make me more fertile?
Indirectly, yes, and this is the other half of the "Ozempic babies" story. Weight loss can restore ovulation, particularly in PCOS where anovulation is common — which is a benefit if you want to conceive and a surprise if you do not. Women who have not needed reliable contraception for years can find that changes without any announcement. If pregnancy is not the plan, treat contraception as something to revisit when you start treatment rather than something already settled.
How long before trying to conceive should I stop a GLP-1?
At least two months before a planned pregnancy, for both semaglutide and tirzepatide, because of their long half-lives — not when you get a positive test. These medications are not for use in pregnancy. If you conceive unexpectedly while taking one, contact your prescriber promptly rather than waiting for your next scheduled appointment.
Do GLP-1 medications work for PCOS?
The evidence here is among the strongest for any off-label GLP-1 use. Insulin resistance is documented in clamp studies in about 75% of women with polycystic ovary syndrome, and GLP-1 receptor agonists act directly on that. A meta-analysis of randomised controlled trials found GLP-1 agonists promoted both weight loss and hormonal regulation in women with PCOS and obesity, and liraglutide specifically reduced visceral fat — the deep abdominal fat most closely tied to insulin resistance. Some patients report more predictable menstrual cycles as insulin resistance improves. Prescribing has followed: among women with PCOS, semaglutide or tirzepatide use rose from 2.4% in 2021 to 17.6% in 2025.
Why is weight harder to manage after menopause?
Falling oestrogen shifts where the body stores fat, favouring visceral abdominal fat over subcutaneous fat, and that pattern is more metabolically harmful. Muscle mass also declines with age and with oestrogen loss, and since muscle is metabolically active, losing it lowers resting energy expenditure. The practical consequence is that the same eating pattern that maintained weight at 40 may not at 50 — which is a physiological change, not a failure of willpower.
Do I need to worry about muscle loss on a GLP-1?
It deserves attention, particularly for women over 40 who already face age- and oestrogen-related muscle loss. Rapid weight loss of any kind takes some lean mass along with fat, and starting from a lower muscle baseline makes that more consequential. The countermeasures are well established and unglamorous: prioritise protein intake and do resistance training throughout treatment. Raise it with your prescriber rather than waiting for it to become a problem.
What do doctors say about compounded bioidentical hormones?
Professional bodies are notably cautious. ACOG's clinical consensus is that compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved formulations exist, and that clinicians should counsel patients that FDA-approved therapies are recommended over compounded ones. ACOG has also noted that "bioidentical hormone" is often used as a marketing term implying these preparations are more natural or safer than FDA-approved medications, and that evidence supporting those claims is lacking. The 2020 National Academies report reviewed the same question and found the evidence base thin. The North American Menopause Society has acknowledged a narrower case — patients who genuinely cannot use an approved product, for example because of an allergy to an excipient.
Is "bioidentical" the same as "natural" or "safer"?
No. Bioidentical means the hormone molecule is structurally identical to the one your body produces — and many FDA-approved products are also bioidentical, including approved estradiol and micronised progesterone. The meaningful distinction is not bioidentical versus synthetic; it is FDA-approved versus compounded. Compounded preparations have not been through FDA review for potency, purity or consistency, which is the same caveat that applies to compounded GLP-1s.
Can I take hormone therapy and a GLP-1 at the same time?
Many women do, and there is no general prohibition — but this is specifically a question for a clinician who can see both prescriptions, not something to resolve from two separate telehealth intakes that do not know about each other. Tell each provider what the other has prescribed. If you want both managed together, some providers we review handle weight and hormones in one place; our Alloy review covers that model.
Where to Go Next
- Alloy review — a provider built specifically for women in perimenopause and menopause, handling hormones and weight together
- Protein and satiety — the muscle-retention half of losing weight after 40
- GLP-1 provider reviews — every provider we have researched, with published pricing
Medical Disclaimer
We're not doctors, and this article is for education only — it isn't medical advice. GLP-1 medications are prescription-only and require evaluation by a licensed healthcare provider. Individual results vary widely, and only a clinician who knows your history can determine what is safe and appropriate for you. See our full medical disclaimer.
Keep Comparing
Every provider we've researched, with published pricing, medication type, and what's actually included.
Affiliate Disclosure: This article may contain affiliate links. If you sign up through one, we may earn a commission at no additional cost to you. We do not accept payment for favorable coverage. Read our full affiliate disclosure policy.